These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1156 related items for PubMed ID: 21354370

  • 21. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
    Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J, CLEOPATRA study group.
    Lancet Oncol; 2020 Apr; 21(4):519-530. PubMed ID: 32171426
    [Abstract] [Full Text] [Related]

  • 22. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ, CLASSIC trial investigators.
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [Abstract] [Full Text] [Related]

  • 23. Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.
    Láng I, Bell R, Feng FY, Lopez RI, Jassem J, Semiglazov V, Al-Sakaff N, Heinzmann D, Chang J.
    Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):81-9. PubMed ID: 24051172
    [Abstract] [Full Text] [Related]

  • 24. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [Abstract] [Full Text] [Related]

  • 25. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, AZURE investigators.
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [Abstract] [Full Text] [Related]

  • 26. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Hoersch S, Smitt M, Wildiers H.
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [Abstract] [Full Text] [Related]

  • 27. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.
    J Clin Oncol; 2014 Jul 10; 32(20):2159-65. PubMed ID: 24912899
    [Abstract] [Full Text] [Related]

  • 28. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.
    J Clin Oncol; 2010 Jul 20; 28(21):3422-8. PubMed ID: 20530280
    [Abstract] [Full Text] [Related]

  • 29. [Breast cancer: HER2 changes one's cards on the table].
    Lopez M.
    Clin Ter; 2005 Jul 20; 156(5):255-62. PubMed ID: 16382976
    [Abstract] [Full Text] [Related]

  • 30. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 31. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.
    Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM, TEACH investigators.
    Lancet Oncol; 2013 Jan 20; 14(1):88-96. PubMed ID: 23234763
    [Abstract] [Full Text] [Related]

  • 32. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A, Smith I.
    Breast; 2011 Oct 20; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [Abstract] [Full Text] [Related]

  • 33. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, Kerbrat P, Dupré PF, Bachelot T, Gabelle P, Giard S, Coeffic D, Bougnoux P, Prevost JB, Paintaud G, Thibault G, Hernandez J, Coudert M, Arnould L, Berriolo-Riedinger A.
    Lancet Oncol; 2014 Dec 20; 15(13):1493-1502. PubMed ID: 25456368
    [Abstract] [Full Text] [Related]

  • 34. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
    Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG, Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O, Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L, Henschel V, Deurloo RJ, Pallaud C, Bell R.
    Lancet Oncol; 2013 Sep 20; 14(10):933-42. PubMed ID: 23932548
    [Abstract] [Full Text] [Related]

  • 35. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A, ExteNET Study Group.
    Lancet Oncol; 2017 Dec 20; 18(12):1688-1700. PubMed ID: 29146401
    [Abstract] [Full Text] [Related]

  • 36. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
    Thuss-Patience PC, Shah MA, Ohtsu A, Van Cutsem E, Ajani JA, Castro H, Mansoor W, Chung HC, Bodoky G, Shitara K, Phillips GDL, van der Horst T, Harle-Yge ML, Althaus BL, Kang YK.
    Lancet Oncol; 2017 May 20; 18(5):640-653. PubMed ID: 28343975
    [Abstract] [Full Text] [Related]

  • 37. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT.
    Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA.
    Health Technol Assess; 2020 Aug 20; 24(40):1-190. PubMed ID: 32880572
    [Abstract] [Full Text] [Related]

  • 38. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X, Mariani P, Andre F, Chan A, Lipatov O, Chan S, Wardley A, Greil R, Moore N, Prot S, Pallaud C, Semiglazov V.
    J Clin Oncol; 2013 May 10; 31(14):1719-25. PubMed ID: 23569311
    [Abstract] [Full Text] [Related]

  • 39. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H, Bono P, Kataja V, Alanko T, Kokko R, Asola R, Utriainen T, Turpeenniemi-Hujanen T, Jyrkkiö S, Möykkynen K, Helle L, Ingalsuo S, Pajunen M, Huusko M, Salminen T, Auvinen P, Leinonen H, Leinonen M, Isola J, Kellokumpu-Lehtinen PL.
    J Clin Oncol; 2009 Dec 01; 27(34):5685-92. PubMed ID: 19884557
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
    Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P.
    Lancet Oncol; 2012 Jan 01; 13(1):25-32. PubMed ID: 22153890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 58.